Skip to main content

Building a leading microbiome company in oncology

We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.

See News

Corporate profile

We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.

Press Releases

Press Releases

MaaT Pharma Awarded France Relance Government Grant to Accelerate Development in Immuno-Oncology and Support Manufacturing of Next Generation Microbiome Therapies

MaaT Pharma awarded non-dilutive funding of EURO 1.9 million for its “MEPA” project through the…
Press Releases
MaaT Pharma, lauréat de France Relance, accélère son développement dans l’immuno-oncologie et la production de médicaments microbiote de nouvelle génération
Press Releases
MaaT Pharma Announces DSMB Approval to Proceed to Cohort 4 out of 5 in Phase 1b CIMON Trial Testing Capsule Formulation of Microbiome Ecosystem Therapy
Press Releases
MaaT Pharma Announces Publication of Results from Completed Phase 1/2 ODYSSEE Clinical Trial in Nature Communications
Press Releases
Lancement de l’Alliance Promotion Microbiote

See more